https://www.immunocore.com/investors/news/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_b541aae032f58bf8fdbdeabb137fc49f/immunocore/files/theme/images/logo-sm.png /investors Equisolve Investor Relations Suite https://www.immunocore.com/investors/news/press-releases/detail/140/immunocore-to-present-at-upcoming-investor-conferences Mon, 09 Nov 26 07:00:00 -0500 https://www.immunocore.com/investors/news/press-releases/detail/140/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/139/immunocore-presents-promising-data-from-phase-12-trial-cohort-evaluating-brenetafusp-plus-kimmtrak-tebentafusp-tebn-in-metastatic-uveal-melanoma Fri, 06 Nov 26 12:00:00 -0500 https://www.immunocore.com/investors/news/press-releases/detail/139/immunocore-presents-promising-data-from-phase-12-trial-cohort-evaluating-brenetafusp-plus-kimmtrak-tebentafusp-tebn-in-metastatic-uveal-melanoma https://www.immunocore.com/investors/news/press-releases/detail/138/immunocore-reports-third-quarter-financial-results-and-provides-a-business-update Fri, 06 Nov 26 09:00:00 -0500 https://www.immunocore.com/investors/news/press-releases/detail/138/immunocore-reports-third-quarter-financial-results-and-provides-a-business-update https://www.immunocore.com/investors/news/press-releases/detail/137/immunocore-will-present-phase-1-data-for-brenetafusp-plus-kimmtrak-tebentafusp-tebn-in-metastatic-uveal-melanoma-during-a-late-breaking-oral-session-at-the-2026-sitc-meeting Thu, 29 Oct 26 09:00:00 -0400 https://www.immunocore.com/investors/news/press-releases/detail/137/immunocore-will-present-phase-1-data-for-brenetafusp-plus-kimmtrak-tebentafusp-tebn-in-metastatic-uveal-melanoma-during-a-late-breaking-oral-session-at-the-2026-sitc-meeting https://www.immunocore.com/investors/news/press-releases/detail/136/immunocore-announces-first-patient-dosed-in-the-phase-1-trial-of-imc-s118ai-its-first-tissue-specific-autoimmune-candidate-for-patients-with-type-1-diabetes Thu, 15 Oct 26 07:00:00 -0400 https://www.immunocore.com/investors/news/press-releases/detail/136/immunocore-announces-first-patient-dosed-in-the-phase-1-trial-of-imc-s118ai-its-first-tissue-specific-autoimmune-candidate-for-patients-with-type-1-diabetes https://www.immunocore.com/investors/news/press-releases/detail/135/immunocore-announces-achievement-of-target-enrollment-in-registrational-tebe-am-trial-with-kimmtrak-tebentafusp-in-previously-treated-advanced-melanoma Mon, 14 Sep 26 07:00:00 -0400 https://www.immunocore.com/investors/news/press-releases/detail/135/immunocore-announces-achievement-of-target-enrollment-in-registrational-tebe-am-trial-with-kimmtrak-tebentafusp-in-previously-treated-advanced-melanoma https://www.immunocore.com/investors/news/press-releases/detail/134/immunocore-to-present-at-upcoming-investor-conferences Tue, 01 Sep 26 07:00:00 -0400 https://www.immunocore.com/investors/news/press-releases/detail/134/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/133/immunocore-reports-second-quarter-financial-results-and-provides-a-business-update Thu, 06 Aug 26 07:00:00 -0400 https://www.immunocore.com/investors/news/press-releases/detail/133/immunocore-reports-second-quarter-financial-results-and-provides-a-business-update https://www.immunocore.com/investors/news/press-releases/detail/132/immunocore-to-report-second-quarter-2026-financial-results-and-host-call-on-august-6-2026 Thu, 30 Jul 26 07:00:00 -0400 https://www.immunocore.com/investors/news/press-releases/detail/132/immunocore-to-report-second-quarter-2026-financial-results-and-host-call-on-august-6-2026 https://www.immunocore.com/investors/news/press-releases/detail/131/immunocore-presents-updated-phase-1-data-of-brenetafusp-in-patients-with-heavily-pretreated-advanced-melanoma Sun, 31 May 26 08:00:00 -0400 https://www.immunocore.com/investors/news/press-releases/detail/131/immunocore-presents-updated-phase-1-data-of-brenetafusp-in-patients-with-heavily-pretreated-advanced-melanoma